Evidence map›Paper›PMID 37498289›Full record

ArticleMicrobial biotechnology2024

From accurate genome sequence to biotechnological application: The thermophile Mycolicibacterium hassiacum as experimental model.

Mercedes Sánchez-Costa, Susanne Gola, Marta Rodríguez-Sáiz, José-Luis Barredo, Aurelio Hidalgo, José Berenguer

Abstract read
In one paragraph

Article in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mercedes Sánchez-CostaDepartment of Molecular Biology, Faculty of Sciences, Centre for Molecular Biology (UAM-CSIC), University Institute for Molecular Biology, Madrid, Spain.
Susanne GolaDepartment of Medical Technology and Biotechnology, Ernst-Abbe-Hochschule Jena, University of Applied Sciences, Jena, Germany.
Marta Rodríguez-SáizDepartment of Biotechnology, Curia, Parque Tecnológico de León, León, Spain.
José-Luis BarredoDepartment of Biotechnology, Curia, Parque Tecnológico de León, León, Spain.
Aurelio HidalgoDepartment of Molecular Biology, Faculty of Sciences, Centre for Molecular Biology (UAM-CSIC), University Institute for Molecular Biology, Madrid, Spain.ORCID 0000-0001-5740-5584
José BerenguerDepartment of Molecular Biology, Faculty of Sciences, Centre for Molecular Biology (UAM-CSIC), University Institute for Molecular Biology, Madrid, Spain.ORCID 0000-0002-9689-6272

Funding

H2020 European Research Council GA 685474-2Ministerio de Ciencia e Innovación PID2019-109073RB-100
6 · The paper itself

Abstract

Mycobacteria constitute a large group of microorganisms belonging to the phylum Actinobacteria encompassing some of the most relevant pathogenic bacteria and many saprophytic isolates that share a unique and complex cell envelope. Also unique to this group is the extensive capability to use and synthesize sterols, a class of molecules that include active signalling compounds of pharmaceutical use. However, few mycobacterial species and strains have been established as laboratory models to date, Mycolicibacterium smegmatis mc

Indexed as

BacteriaMycobacteriaceaePlasmids

Identifiers

PMID37498289
PMCPMC10832570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.